Pulse ·

Sarcopenic obesity triples type 2 diabetes risk — muscle mass matters

By Dr HB Lo, FACRRM 4 min read
Verdict Yes — worth knowing about

A Curtin University study of 479,607 people, published in Diabetes Care, found that sarcopenic obesity — a combination of excess body fat and low muscle mass — increases type 2 diabetes risk 3.5 times compared to a healthy body composition. This is 91% higher than the risk from low muscle mass alone and 19% higher than from excess fat alone. The link was particularly strong in women and adults under 60. The finding adds clinical weight to a key insight: for metabolic health, what the body is made of matters, not just how much it weighs.

What just happened

A new study published in Diabetes Care has found that the combination of low muscle mass and excess body fat — known clinically as sarcopenic obesity — raises the risk of developing type 2 diabetes 3.5 times compared to a healthy body composition.

The research, led by Professor Mario Siervo and colleagues at Curtin University, followed 479,607 people from the UK Biobank over a median of 14.2 years. In that time, 32,948 participants developed type 2 diabetes. The dataset allowed researchers to separate the contributions of excess fat and low muscle — and to show that having both simultaneously is considerably more dangerous than either alone.

Sarcopenic obesity carries 19% more risk than obesity without low muscle mass, and 91% more risk than low muscle mass without excess fat. The relationship was especially pronounced in women and adults under 60 — exactly the demographic for whom prevention conversations in general practice tend to matter most.

The both-and

Weight is not the whole story

More than 1.3 million Australians live with type 2 diabetes, and many more are on the trajectory toward it. Prevention has typically centred on weight and dietary change — and those remain important. But this study adds precision to the picture.

BMI and total body weight do not distinguish between fat and muscle. Two people can have an identical BMI — one with high muscle mass and moderate fat, one with low muscle mass and high fat — and their metabolic risk profiles look very different. The Curtin study suggests the second person faces substantially higher diabetes risk, and that this distinction has been underweighted in clinical risk conversations.

Lead author Zhongyang Guan noted that “maintaining muscle strength and muscle mass may be just as important as managing body weight.” Professor Siervo added that “assessing muscle health could help identify people at high risk earlier” — pointing toward a practical shift: muscle health as a screening consideration alongside traditional metabolic markers.

Why this matters especially for women under 60

Muscle mass declines naturally with age — a process called sarcopenia. In women, the hormonal changes of perimenopause and menopause accelerate this decline, often without obvious symptoms. Fat redistribution during this period (moving from subcutaneous to visceral storage) compounds the metabolic picture. The result is that many women in their 40s and early 50s are moving toward a body composition that looks exactly like what this study identifies as high risk — not because of anything they are doing wrong, but because of the biology of mid-life.

The study’s finding that the link is “particularly strong in women and adults under 60” is not incidental — it is pointing at the most active window for prevention.

This also challenges a common narrative. Women who exercise regularly, maintain a stable weight, and feel reasonably well may still be accumulating risk through gradual muscle loss if their activity does not include resistance-based movement. Cardiovascular exercise preserves heart and lung fitness; it does not reliably preserve muscle mass. These are different physiological targets.

What muscle health assessment looks like in practice

The study used measures available in large-scale biobank data, including grip strength and appendicular lean mass (muscle in the limbs). In a GP setting, simpler proxy markers can point in the right direction: reported activity patterns, grip dynamometry, and careful history-taking about functional decline. A patient reporting increasing difficulty with stairs, carrying groceries, or recovery from mild exertion may be showing early muscle health changes well before any blood marker flags.

Australian GPs can incorporate muscle function questions into metabolic risk reviews — particularly for women in the perimenopausal years and anyone with a BMI in the overweight range who is sedentary.

My two cents

This study does not change what good prevention looks like — it sharpens the message.

For years the dominant frame in metabolic risk conversations has been weight loss. What research like this makes increasingly clear is that body composition is the more precise target. Losing weight by losing muscle moves the dial in the wrong direction. Conversely, having a BMI in the “healthy” range while carrying low muscle and high visceral fat does not make the risk disappear.

The practical translation: for anyone motivated to reduce their type 2 diabetes risk, conversations about resistance exercise — building and maintaining muscle — belong alongside conversations about diet and weight. Resistance training two to three times per week, at whatever intensity suits the person, maintains muscle mass during the period when it is most at risk.

For women in their 40s: the biology of perimenopause quietly works against muscle mass. Regular resistance-based movement is one of the most evidence-supported strategies for long-term metabolic health. Australian physical activity guidelines already recommend muscle-strengthening activity on at least two days per week — this research makes the case for taking that recommendation seriously rather than defaulting to walks alone.

If a metabolic or musculoskeletal review is not something that has come up at a recent appointment, it may be worth asking your GP whether one is appropriate.

Verdict: yes — worth knowing about.

Sources cited

  1. “Study links muscle health to diabetes risk.” newsGP (RACGP), 14 July 2026. https://www1.racgp.org.au/newsgp/clinical/study-links-muscle-health-to-diabetes-risk
  2. Guan Z, Siervo M, et al. “Sarcopenic obesity and type 2 diabetes risk.” Diabetes Care, 2026. https://diabetesjournals.org/care/article/doi/10.2337/dc26-0797
  3. AIHW. Diabetes in Australia. https://www.aihw.gov.au/reports/diabetes/diabetes
  4. Australian Government Department of Health. Physical activity guidelines. https://www.health.gov.au/topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians

Frequently asked questions

  • How do I know if I have sarcopenic obesity?

    Sarcopenic obesity is not routinely tested in standard GP visits, but your GP can assess it through a combination of body weight, waist circumference, reported muscle function, and grip strength. If you have noticed increasing difficulty with physical tasks — climbing stairs, carrying bags, recovering from exertion — that is worth raising. A GP Management Plan can coordinate referral to an exercise physiologist for a formal functional assessment if clinically indicated.

  • What kind of exercise protects muscle mass?

    Resistance-based exercise — using weights, resistance bands, or body weight exercises such as squats and push-ups — is the most evidence-supported approach for preserving and building muscle mass at any age. Current Australian physical activity guidelines recommend muscle-strengthening activity on at least two days per week, alongside aerobic movement. An exercise physiologist can design a programme appropriate to your current fitness level and any existing conditions.